HUTCHMED and Innovent’s New Drug Application for Renal Cancer Therapy Accepted in China

HUTCHMED (China) ( (HK:0013) ) has provided an update.

HUTCHMED and Innovent Biologics have announced the acceptance of their New Drug Application in China for a combination therapy of fruquintinib and sintilimab aimed at treating advanced renal cell carcinoma. This development marks a significant advancement in addressing the unmet medical needs for patients who have failed prior treatments, potentially strengthening HUTCHMED’s position in the oncology market and providing a new treatment option for stakeholders.

The most recent analyst rating on (HK:0013) stock is a Buy with a HK$35.61 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.

More about HUTCHMED (China)

HUTCHMED (China) Limited operates in the pharmaceutical industry, focusing on the development and commercialization of targeted therapies and immunotherapies for cancer treatment. The company collaborates with global partners to enhance its product offerings and market reach.

Average Trading Volume: 7,446,828

Technical Sentiment Signal: Sell

Current Market Cap: HK$18.83B

For a thorough assessment of 0013 stock, go to TipRanks’ Stock Analysis page.